CAJ | 학술논문

目的探讨吉西他滨联合奥沙利铂治疗胰腺癌的临床治疗效果及安全性,为临床用药提供依据.方法选择2010年8月~2011年6月在我院肿瘤科治疗的58例胰腺癌患者,随机分为两组,每组29例,对照组患者单用吉西他滨治疗,观察组给予吉西他滨联合奥沙利铂治疗,比较两组患者治疗后的客观有效率、不良反应及生存期.结果对照组患者的客观有效率为79.3%(23/29),观察组患者的客观有效率为96.6%(28/29),显著高于对照组(P<0.05);对照组患者的临床受益率为58.6%(17/29),观察组患者的临床受益率为75.9%(22/29),亦较对照组显著升高(P<0.05);观察组患者不良反应的发生率显著低于对照组(P<0.05),患者的平均生存时间(6.8±1.3年)显著长于对照组(2.3±1.1年),组间差异具有统计学意义(P<0.05).结论吉西他滨联合奥沙利铂治疗胰腺癌较单用吉西他滨可以显著提高治疗的客观有效率,延长患者的生存期,并降低药物的不良反应,值得临床推广使用.
목적탐토길서타빈연합오사리박치료이선암적림상치료효과급안전성,위림상용약제공의거.방법선택2010년8월~2011년6월재아원종류과치료적58례이선암환자,수궤분위량조,매조29례,대조조환자단용길서타빈치료,관찰조급여길서타빈연합오사리박치료,비교량조환자치료후적객관유효솔、불량반응급생존기.결과대조조환자적객관유효솔위79.3%(23/29),관찰조환자적객관유효솔위96.6%(28/29),현저고우대조조(P<0.05);대조조환자적림상수익솔위58.6%(17/29),관찰조환자적림상수익솔위75.9%(22/29),역교대조조현저승고(P<0.05);관찰조환자불량반응적발생솔현저저우대조조(P<0.05),환자적평균생존시간(6.8±1.3년)현저장우대조조(2.3±1.1년),조간차이구유통계학의의(P<0.05).결론길서타빈연합오사리박치료이선암교단용길서타빈가이현저제고치료적객관유효솔,연장환자적생존기,병강저약물적불량반응,치득림상추엄사용.
@@@@Objective To study the clinical efficacy and safety of gemcitabine combined oxaliplatin in the treatment of pancreatic cancer and provide references for the further clinical application. Methods 58 cases of pancreatic cancer patients admitted in our hospital from August 2010 to June 2011were randomly divided into two groups (29 cases in each group). The control group was treated by gemcitabine, while the observation group was given gemcitabine combined oxaliplatin. The objective response rate, adverse reaction and survival period were compared between the two groups. Results The objective response rate of observation group was 96.6% (28/29), which was significantly higher than that of the control group (79.3%, P<0.05). The clinical benefit rate of observation group was 75.9% (22/29), which was also significantly higher than that of the control group (58.6%, P<0.05). The incidence rate of adverse reactions of the observation group was significantly lower than that of the control group (P<0.05). The average survival time of observation group was 6.8±1.3 years, which was obviously longer than that of the control group (2.3±1.1) (P<0.05). Conclusion Compared with treatment with Gemcitabine alone, Gemcitabine combined with oxaliplatin may effectively improve the objective response rate, prolong the survival period, and reduce the adverse reaction of patients with pancreatic cancer. It is worth of clinical application.